Give Kids a Chance Act of 2025
4/5/2025, 11:03 AMSummary of Bill S 932
Bill 119 s 932, also known as the Pediatric Cancer Targeted Therapy Act, aims to make important changes to the Federal Food, Drug, and Cosmetic Act in order to improve the investigation and treatment of pediatric cancer through molecularly targeted therapies.The bill specifically focuses on the development and approval process for drugs that target specific molecular pathways in pediatric cancer patients. These targeted therapies have shown promise in treating certain types of cancer by attacking the specific genetic mutations that drive the growth of cancer cells.
One of the key provisions of the bill is to streamline the regulatory process for these targeted therapies, making it easier for pharmaceutical companies to conduct clinical trials and seek approval for pediatric cancer treatments. This is intended to speed up the availability of potentially life-saving drugs for children with cancer. Additionally, the bill includes provisions to encourage collaboration between researchers, clinicians, and pharmaceutical companies in the development of targeted therapies for pediatric cancer. This collaboration is seen as crucial in advancing the field of pediatric oncology and improving outcomes for young cancer patients. Overall, Bill 119 s 932 aims to address the unique challenges and needs of pediatric cancer research and treatment by promoting the development of molecularly targeted therapies and fostering collaboration among key stakeholders in the fight against childhood cancer.
Read the Full Bill
Current Status of Bill S 932
Bill S 932 is currently in the status of Bill Introduced since March 11, 2025. Bill S 932 was introduced during Congress 119 and was introduced to the Senate on March 11, 2025. Bill S 932's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of March 11, 2025Bipartisan Support of Bill S 932
Total Number of Sponsors
4Democrat Sponsors
0Republican Sponsors
4Unaffiliated Sponsors
0Total Number of Cosponsors
5Democrat Cosponsors
4Republican Cosponsors
1Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill S 932
Primary Policy Focus
HealthAlternate Title(s) of Bill S 932
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.Comments
Most relevant
Sponsors and Cosponsors of S 932
Latest Bills
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Review of Final Rule Reclassification of Major Sources as Area Sources Under Section 112 of the Clean Air Act".
Bill HJRES 79April 8, 2025
Medicare Dental, Vision, and Hearing Benefit Act of 2025
Bill HR 2045April 8, 2025
Lactation Spaces for Veteran Moms Act
Bill HR 1646April 8, 2025
DMEPOS Relief Act of 2025
Bill HR 2005April 8, 2025
Physicians for Underserved Areas Act
Bill S 1044April 8, 2025
NICS Data Reporting Act
Bill HR 2267April 8, 2025
Providing for consideration of the joint resolution (S.J. Res. 18) disapproving the rule submitted by the Bureau of Consumer Financial Protection relating to "Overdraft Lending: Very Large Financial Institutions"; providing for consideration of the joint resolution (S.J. Res. 28) disapproving the rule submitted by the Bureau of Consumer Financial Protection relating to "Defining Larger Participants of a Market for General-Use Digital Consumer Payment Applications"; providing for consideration of the bill (H.R. 1526) to amend title 28, United States Code, to limit the authority of district courts to provide injunctive relief, and for other purposes; providing for consideration of the bill (H.R. 22) to amend the National Voter Registration Act of 1993 to require proof of United States citizenship to register an individual to vote in elections for Federal office, and for other purposes; and for other purposes.
Bill HRES 294April 8, 2025
Providing for consideration of the joint resolution (H.J. Res. 25) providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Internal Revenue Service relating to "Gross Proceeds Reporting by Brokers That Regularly Provide Services Effectuating Digital Asset Sales"; providing for consideration of the bill (H.R. 1156) to amend the CARES Act to extend the statute of limitations for fraud under certain unemployment programs, and for other purposes; providing for consideration of the bill (H.R. 1968) making further continuing appropriations and other extensions for the fiscal year ending September 30, 2025, and for other purposes; and for other purposes.
Bill HRES 211April 8, 2025
SAVE Act
Bill HR 22April 8, 2025
A joint resolution disapproving the rule submitted by the Bureau of Consumer Financial Protection relating to "Overdraft Lending: Very Large Financial Institutions".
Bill SJRES 18April 8, 2025
To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.
Bill HR 1262March 12, 2025
Bipartisan Health Care Act
Bill S 891April 4, 2025